Pune, India, July 2021/MRFR Press Release/- Market Research Future published a half-cooked research report on the Global Endometrial Cancer market.
The endometrial cancer market is expected to witness tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of endometrial cancer. However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.
The Endometrial Cancer Market is anticipated to reach USD 22,187.69 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030
The global endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and diagnostic laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin and, cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Endometrial Cancer Market Research Report
The Americas is expected to dominate the endometrial cancer market during the forecast period. The increasing occurrence of ovarian cancer drives the market in this region. The American Cancer Society estimated that in 2018, 22,240 women are likely to be diagnosed with ovarian cancer. This is expected to influence the market growth during the forecast period.
Europe (UK, Belgium, France, and the Netherlands) is the second largest in the market owing to the increasing prevalence of obesity and growing healthcare expenditure. According to WHO, 23% of the women in Europe were obese in 2014.
Asia-Pacific was projected to be the fastest growing region for the global endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. The Asian Diabetes Prevention Initiative estimated that by 2030 India and China would have a diabetic patient pool with a total of half billion people. This is expected to provide favorable backgrounds for the market to grow.
The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.
Some of the key players in the global endometrial cancer market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.